ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 637

How Often Should SLE Patients Be Tested for Lupus Anticoagulant?

Laurence Magder1 and Michelle Petri 2, 1University of Maryland School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: longitudinal studies and diagnostic criteria, lupus anticoagulant, Systemic lupus erythematosus (SLE), Thrombosis

Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE patients with persistent lupus anticoagulant (LAC) have been observed to be at significantly higher risk of thrombosis.  A common clinical definition of persistent  LAC is to have two confirmed tests for LAC separated in time by at least 12 weeks.  The likelihood of identifying a patient with LAC based on this definition depends on the frequency with which it is assessed. The purpose of this analysis is to determine the impact of frequent repeated testing of LAC on patient identification and clinical outcomes.

Methods: LAC was measured repeatedly in patients in a large American clinical cohort of prevalent and incident SLE patients. (51% Caucasian-American, 40% African American) . Patients were defined as LAC positive at a clinic visit if they had a dRVVT of 45 or more seconds, a mixing study, and then a positive confirmatory test.  For 20% of the patients, the confirmatory test was missing and these values were imputed using multiple imputation based largely on the value of dRVVT.  Persistent lupus anticoagulant was defined as having two consecutive visits with confirmed lupus anticoagulant separated by at least 12 weeks. We determined the number of patients who would be identified as having persistent LAC under two scenarios: 1) if only 5 LAC assessments were made, or 2) if multiple repeated assessments were made.  In addition, we determined whether those identified with persistent LAC based on multiple repeat assessments but who were not identified based on only 5 assessments were at increased risk of thrombosis.  This was based on discrete survival analysis including followup that occurred after at least 5 LAC assessments was included.

Results: The analysis was based on 36,218 clinical tests of LAC from 1457 different patients who had at least 5 LAC tests.  The number of tests per patient ranged from 5 to 74 with a mean of 25.  Based on only the first 5 tests per patient, the prevalence  of persistent LAC was 11.7%.  Based on all the LAC tests, the prevalence of persistent LAC was found to be 15.8%.  Table 1 shows the rates of thrombosis in months defined by LAC classification based on all prior tests.  In those months that were not preceded by persistent LAC the rate of thrombosis was 1.3 per 1000 person-months.  In those months that were preceded by a diagnosis of LAC based on the patient’s first 5 LAC tests, the rate of thrombosis was 2.5 per 1000 person-months (p=0.018 relative to months without LAC).  In those months that were not classified as having prior persistent LAC based on the patient’s first 5 LAC tests, but were classified as having persistent LAC based on all prior LAC tests, the rate of thrombosis was 1.8 per 1000 person months (p=0.46 relative to months without LAC).

Conclusion: 26% of those with persistent LAC are missed if LAC assessment is based only on the first 5 LAC tests. However, those classified as having LAC based on their first 5 tests are at highest risk of thrombosis.  This information can inform decision-making related to frequency of LAC testing.


Table 1


Disclosure: L. Magder, None; M. Petri, Eli Lilly and Company, 5, Exagen, 2, 5.

To cite this abstract in AMA style:

Magder L, Petri M. How Often Should SLE Patients Be Tested for Lupus Anticoagulant? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/how-often-should-sle-patients-be-tested-for-lupus-anticoagulant/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/how-often-should-sle-patients-be-tested-for-lupus-anticoagulant/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology